Nvidia sold its entire stake in a drug-discovery company at the end of last year. ARK Invest is buying the stock.

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Wednesday announced that its Board of Directors has unanimously approved that Chief R&D and Commercial Officer ...

Palantir, Tempus and Recursion are racing to reshape drug discovery with AI and data-driven platforms. Investors are watching closely as these disruptors challenge Big Pharma’s traditional R&D with ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...